Skip to main content

Illumina

Illumina, Inc. is an American biotechnology enterprise that develops, manufactures, and markets life science systems and integrated tools for genetic analysis. The company structures its business operations through primary reportable business segments, led by Core Illumina and specialized genomic diagnostics divisions. Its technical product portfolio comprises high-throughput DNA sequencing platforms, microarrays, sequencing chemistry consumables, and genomic data analysis software. Principal revenue drivers consist of high-margin recurring sales of sequencing consumables and reagents, system hardware sales of sequencers like NovaSeq, and technical service support. Illumina serves broad global health end markets including academic research centers, biopharmaceutical companies, clinical diagnostic laboratories, oncology clinics, and agricultural research institutes in over 150 countries. The corporation holds a dominant global market position as the primary provider of next-generation sequencing (NGS) technology and instruments worldwide. Headquartered in San Diego, California, the company's common stock is publicly listed on the Nasdaq Global Select Market under the ticker symbol ILMN and is included in the S&P 500 index.

75 of the funds FundTelligence covers report a position in Illumina.

Legal name
Illumina Inc.
Sector
Health Care
Country
United States
Funds holding it
75
Exposure themes
Genomics & Profiling, Precision Medicine & Genomics, Sequencing

Funds holding Illumina

Showing the 8 largest of 75 funds holding it.

Loading...